Drugs / CREPT-618
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07364357 | Sep 2025 → Aug 2026 overdue | hepatocellular carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CREPT-618 | “A Phase I Study of CREPT-618 in Locally Advanced HCC” NCT07364357 ↗ |
| Modality | Oligonucleotide (other) | “small nucleic acid drugs” NCT07307053 ↗ |
| Route | Subcutaneous | “subcutaneous injections of CREPT-618 administered once every two weeks” NCT07364357 ↗ |